A new salmonella vaccine that claims earlier onset of immunity and longer, stronger suppression of the bug launched to the UK market at this year’s Pig & Poultry Fair.
Salmovac 440 is a live vaccine manufactured by IDT Biologika, and will be marketed by Hysolv Animal Health in the UK and Ireland.
It is given orally through water supply in a three-dose regime, protecting against both Salmonella enteritidis (SE) and Salmonella typhimurium. It also confers protection against other SE strains and the newly emerging monophasic Salmonella typhimurium strains.
Daniel Windhorst, salmonella specialist at IDT Biologika, said the vaccine strain was robust, meaning it remained effective in less than ideal delivery conditions.
He told the fair that the first dose can be administered from day 1, followed by a second dose at 6 weeks and a third as early as 11 weeks.
Salmovac 440 protects chicks after 6 days and remains effective for up to 63 weeks after the third vaccination, providing an extra 4 weeks of protection, when compared with competitor products, Dr Windhorst said.
The earlier final vaccination, at 11 weeks, means that pullets can be moved to the laying house as early as 16-weeks-old if required – a significant management advantage on some farms.
During the development of the vaccines it was found that the third live vaccination tended to “shut down” any prolonged shedding of the vaccine strain.
This, coupled with the earlier vaccination at 11 weeks, helps reduce the chances the strain will transfer to the layer house.
To comply with the British Lion Code of Practice pullet rearers are required to test their birds for salmonella infection before they are moved to the layer house.
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
“Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important,” said Dr Windhorst.
Author: Jake Davies
"*" indicates required fields
Notifications
Your Privacy Matters
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (24) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.